Rheumatology 2000; 39: 1014-1019
© 2000 British Society for Rheumatology
Outcome of lupus pregnancy: a controlled study
Department of Internal Medicine, Division of Rheumatology, Medical School, University of Ioannina and
1 Obstetrics and Gynaecology Clinic, Hatzikosta General Hospital of Ioannina, Greece
Objective. The reciprocal relationship between systemic lupus erythematosus (SLE) and pregnancy was investigated in a controlled study.
Method. The outcome of 47 pregnant SLE patients with 59 pregnancies was compared with that of 57 healthy control women and 59 pregnancies. The results were also compared with those of 59 non-pregnant control SLE patients.
Results. All pregnant SLE patients but one were in remission at the onset of pregnancy and were being treated with low doses of prednisone (
10 mg/day, 26 patients), hydroxychloroquine (200 mg/day, eight patients) or azathioprine (100 mg/day, one patient). Sixty-one per cent of SLE pregnancies were delivered at term and 5% had premature deliveries. The rates of spontaneous abortion and total fetal loss were significantly higher in the mothers with SLE than in the control population (P < 0.001 and P < 0.01 respectively). None of the 39 neonates from SLE mothers had neonatal lupus, anti-Ro(SSA) or anti-La(SSB) antibodies. Eight out of 59 pregnancies of SLE mothers (13.5%) were characterized by disease exacerbation. Arthralgias or arthritis, fever and skin lesions were observed more frequently in the mothers with SLE than in the non-pregnant group (P < 0.001). Renal involvement was found in three SLE patients during pregnancy and in three after delivery.
Conclusions. Pregnant women with SLE are at high risk of fetal loss and spontaneous abortion. Pregnancy does not cause life-threatening manifestations of the disease. Thus, for a better outcome of lupus pregnancy, it is essential to control disease activity and to achieve clinical remission.
KEY WORDS: Systemic lupus erythematosus, Pregnancy, Outcome, Spontaneous abortion, Fetal loss, Neonatal lupus, Ro(SSA) antibodies, La(SSB) antibodies, Anticardiolipins.
Correspondence to: A. A. Drosos, Department of Internal Medicine, Medical School, University of Ioannina, 451 10 Ioannina, Greece.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Leanos-Miranda, G. Cardenas-Mondragon, A. Ulloa-Aguirre, I. Isordia-Salas, A. Parra, and J. Ramirez-Peredo Anti-prolactin autoantibodies in pregnant women with systemic lupus erythematosus: maternal and fetal outcome Lupus, May 1, 2007; 16(5): 342 - 349. [Abstract] [PDF]
|
|
|
|
 |
|
 R. M. Andrade, G. McGwin Jr, G. S. Alarcon, M. L. Sanchez, A. M. Bertoli, M. Fernandez, B. J. Fessler, M. Apte, A. M. Arango, H. M. Bastian, et al. Predictors of post-partum damage accrual in systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (XXXVIII) Rheumatology, November 1, 2006; 45(11): 1380 - 1384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y Molad, T Borkowski, A Monselise, A Ben-Haroush, J Sulkes, M Hod, D Feldberg, and J Bar Maternal and fetal outcome of lupus pregnancy: a prospective study of 29 pregnancies Lupus, February 1, 2005; 14(2): 145 - 151. [Abstract] [PDF]
|
|
|
|
|
|
F Neri, L Chimini, F Bonomi, E Filippini, M Motta, D Faden, A Lojacono, C B. Rebaioli, M Frassi, E Danieli, et al. Neuropsychological development of children born to patients with systemic lupus erythematosus Lupus, October 1, 2004; 13(10): 805 - 811. [Abstract] [PDF]
|
|
|
|
|
|
J. Cortes-Hernandez, J. Ordi-Ros, F. Paredes, M. Casellas, F. Castillo, and M. Vilardell-Tarres Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies Rheumatology, June 1, 2002; 41(6): 643 - 650. [Abstract] [Full Text] [PDF]
|
|